Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men.


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
01 2019
Historique:
received: 08 06 2018
accepted: 15 08 2018
pubmed: 25 9 2018
medline: 7 6 2019
entrez: 25 9 2018
Statut: ppublish

Résumé

Causes of high mortality of prostate cancer in men of African ancestry living in the French West Indies are still debated, between suspicions of environmental factors and genetic susceptibility. We report an integrated genomic study of 25 tumour tissues from radical prostatectomy of aggressive (defined by International Society of Urological Pathology ≥3) prostate cancer patients (10 African Caribbean and 15 French Caucasian) using single nucleotide polymorphism arrays, whole-genome sequencing, and RNA sequencing. The results show that African Caribbean tumours are characterised by a more frequent deletion at 1q41-43 encompassing the DNA repair gene PARP1, and a higher proportion of intrachromosomal rearrangements including duplications associated with CDK12 truncating mutations. Transcriptome analyses show an overexpression of genes related to androgen receptor activity in African Caribbean tumours, and of PVT1, a long non-coding RNA located at 8q24 that confirms the strong involvement of this region in prostate tumours from men of African ancestry. Patient summary: Mortality of prostate cancer is higher in African Caribbean men than in French Caucasian men. Specificities of the former could be explained by genomic events linked with key genes such as DNA damage pathway genes PARP1, CDK12, and the oncogenic long non-coding RNA gene PVT1 at the 8q24 prostate cancer susceptibility locus.

Identifiants

pubmed: 30245085
pii: S0302-2838(18)30618-3
doi: 10.1016/j.eururo.2018.08.026
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-15

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Laurie Tonon (L)

Synergie Lyon Cancer, Plateforme de Bioinformatique 'Gilles Thomas', Centre Léon Bérard, Lyon, France.

Gaëlle Fromont (G)

CeRePP, Paris, France; CHU de Poitiers, Hôpital de la Miletrie, Poitiers, France; CHRU de Tours, Department of Pathology, Tours, France.

Sandrine Boyault (S)

Centre Léon Bérard, Département de Recherche Translationnelle et de l'Innovation, Génomique des Cancers, Lyon, France.

Emilie Thomas (E)

Synergie Lyon Cancer, Plateforme de Bioinformatique 'Gilles Thomas', Centre Léon Bérard, Lyon, France.

Anthony Ferrari (A)

Synergie Lyon Cancer, Plateforme de Bioinformatique 'Gilles Thomas', Centre Léon Bérard, Lyon, France.

Anne-Sophie Sertier (AS)

Synergie Lyon Cancer, Plateforme de Bioinformatique 'Gilles Thomas', Centre Léon Bérard, Lyon, France.

Janice Kielbassa (J)

Synergie Lyon Cancer, Plateforme de Bioinformatique 'Gilles Thomas', Centre Léon Bérard, Lyon, France.

Vincent Le Texier (V)

Synergie Lyon Cancer, Plateforme de Bioinformatique 'Gilles Thomas', Centre Léon Bérard, Lyon, France.

Aurélie Kamoun (A)

Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, Paris, France.

Nabila Elarouci (N)

Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, Paris, France.

Jacques Irani (J)

CHU de Poitiers, Hôpital de la Miletrie, Poitiers, France.

Luc Multigner (L)

Inserm U1085 - IRSET, Pointe à Pitre, Guadeloupe.

Ivo Glynne Gut (IG)

CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain.

Marta Gut (M)

CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain.

Pascal Blanchet (P)

Inserm U1085 - IRSET, Pointe à Pitre, Guadeloupe; CHU Pointe-à-Pitre/Abymes, Department of Urology, Pointe à Pitre, Guadeloupe.

Aurélien De Reynies (A)

Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, Paris, France.

Géraldine Cancel-Tassin (G)

CeRePP, Paris, France; Sorbonne Université, GRC n(∘)5, ONCOTYPE-URO, Paris, France.

Alain Viari (A)

Synergie Lyon Cancer, Plateforme de Bioinformatique 'Gilles Thomas', Centre Léon Bérard, Lyon, France; INRIA, Montbonnot-Saint Martin, France.

Olivier Cussenot (O)

CeRePP, Paris, France; Sorbonne Université, GRC n(∘)5, ONCOTYPE-URO, Paris, France; Assistance Publique Hôpitaux de Paris, Department of Urology, Academic Hospital Paris Est, Paris, France. Electronic address: olivier.cussenot@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH